Invesco’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $567K | Sell |
335,309
-44,724
| -12% | -$79.4K | ﹤0.01% | 3111 |
|
|
2025
Q4 | $540K | Buy |
380,033
+119,041
| +46% | +$173K | ﹤0.01% | 3169 |
|
|
2025
Q3 | $428K | Buy |
260,992
+52,721
| +25% | +$58.6K | ﹤0.01% | 3295 |
|
|
2025
Q2 | $152K | Buy |
208,271
+21,550
| +12% | +$18.6K | ﹤0.01% | 3581 |
|
|
2025
Q1 | $151K | Buy |
186,721
+120,670
| +183% | +$139K | ﹤0.01% | 3570 |
|
|
2024
Q4 | $91.2K | Buy |
66,051
+4,822
| +8% | +$5.41K | ﹤0.01% | 3637 |
|
|
2024
Q3 | $63.7K | Buy |
61,229
+9,128
| +18% | +$12.5K | ﹤0.01% | 3662 |
|
|
2024
Q2 | $90.1K | Buy |
52,101
+4,788
| +10% | +$9.63K | ﹤0.01% | 3766 |
|
|
2024
Q1 | $113K | Sell |
47,313
-84
| -0.2% | -$207 | ﹤0.01% | 3729 |
|
|
2023
Q4 | $158K | Buy |
47,397
+9,311
| +24% | +$24.9K | ﹤0.01% | 3608 |
|
|
2023
Q3 | $142K | Sell |
38,086
-238,074
| -86% | -$1.1M | ﹤0.01% | 3669 |
|
|
2023
Q2 | $1.18M | Sell |
276,160
-5,985
| -2% | -$35.3K | ﹤0.01% | 2834 |
|
|
2023
Q1 | $1.93M | Sell |
282,145
-59,708
| -17% | -$463K | ﹤0.01% | 2648 |
|
|
2022
Q4 | $2.71M | Buy |
341,853
+26,220
| +8% | +$202K | ﹤0.01% | 2521 |
|
|
2022
Q3 | $3.03M | Sell |
315,633
-17,160
| -5% | -$174K | ﹤0.01% | 2460 |
|
|
2022
Q2 | $2.41M | Buy |
332,793
+4,465
| +1% | +$38.8K | ﹤0.01% | 2619 |
|
|
2022
Q1 | $4.24M | Buy |
328,328
+19,909
| +6% | +$253K | ﹤0.01% | 2457 |
|
|
2021
Q4 | $4.92M | Sell |
308,419
-111,901
| -27% | -$1.96M | ﹤0.01% | 2416 |
|
|
2021
Q3 | $6.75M | Sell |
420,320
-36,718
| -8% | -$538K | ﹤0.01% | 2225 |
|
|
2021
Q2 | $6.32M | Buy |
457,038
+23,276
| +5% | +$330K | ﹤0.01% | 2326 |
|
|
2021
Q1 | $6.34M | Sell |
433,762
-548,803
| -56% | -$9.32M | ﹤0.01% | 2249 |
|
|
2020
Q4 | $17.1M | Buy |
982,565
+60,004
| +7% | +$1.07M | 0.01% | 1518 |
|
|
2020
Q3 | $16.9M | Sell |
922,561
-56,350
| -6% | -$1.05M | 0.01% | 1395 |
|
|
2020
Q2 | $17.5M | Buy |
978,911
+75,389
| +8% | +$1.28M | 0.01% | 1336 |
|
|
2020
Q1 | $14.7M | Buy |
903,522
+608,983
| +207% | +$11.3M | 0.01% | 1344 |
|
|
2019
Q4 | $5.3M | Sell |
294,539
-422,783
| -59% | -$7.8M | ﹤0.01% | 2133 |
|
|
2019
Q3 | $14.5M | Buy |
717,322
+294,236
| +70% | +$5.88M | ﹤0.01% | 1570 |
|
|
2019
Q2 | $9.35M | Buy |
423,086
+40,787
| +11% | +$708K | ﹤0.01% | 1791 |
|
|
2019
Q1 | $5.21M | Buy |
+382,299
| New | +$5.1M | ﹤0.01% | 1978 |
|
|
2015
Q3 | – | Sell |
-197
| Closed | -$6K | – | 3820 |
|
|
2015
Q2 | $6K | Buy |
+197
| New | +$4.98K | ﹤0.01% | 4107 |
|
Other funds holding CHRS
VCM
SB
KKRC
CM
CWG
Invesco's CHRS Position: Q1 2026 in Review
Invesco reduced its Coherus Oncology (CHRS) stake by 12% in Q1 2026, selling an estimated $79.4K and leaving 335,309 shares worth $567K. The position accounts for ﹤0.01% of the portfolio, ranked #3111.
Invesco first reported a position in CHRS in Q2 2015 and has held it in 30 quarters since. The position peaked at $17.5M in Q2 2020. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.
- Invesco held 335,309 shares of Coherus Oncology worth $567K as of Q1 2026.
- Invesco sold 44,724 Coherus Oncology shares in Q1 2026, an estimated $79.4K.
- Coherus Oncology made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3111 holding.
- Invesco first reported a position in Coherus Oncology in Q2 2015 and has held it in 30 quarters since.
- Invesco's Coherus Oncology position peaked at $17.5M in Q2 2020.
- 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.